Page 78 - CIBERDEM2016-ENG

leaD researcher
Simó Canonge, Rafael
Fundación Hospital Universitario Vall d’Hebron - Institut de Recerca (VHIR)
Hospital Vall d’Hebron Passeig Vall D’hebron, 119-129 08035 Barcelona
(+34) 93 489 41 72 [email protected] group Website
gROUP MEMBERS
Staff members: Bogdanov, Patricia Mónica | García Ramírez, Marta | Gutiérrez Carcedo, Patricia Carlota | Ramos Pérez, Lorena | Turch Anguera, Miriea
Associated members: Ciudín, Andreea | Enquix Elena, Natalia | Hernández Pascual, Cristina | Lecube Torello, Albert | Martínez Selva, David | Mesa Manteca, Jorge | Sáez López, Cristina | Sola Adell, Cristina | Villena Delgado, Josep Antoni
Main lines of research
• Physiopathology of diabetic retinopathy
The main aim of this line of research is to identify new targets for the treatment of diabetic retinopathy (DR). In this regard it should be noted that we are coordinating the first clinical trial aimed at testing the effectiveness and safety of neuroprotective agents for the treatment of DR (EudraCT -2012-001200-38). This project has been funded by EC (EUROCONDOR-HEALTH-2011- FP7-278040). In addition, is also noteworthy that we are partners of the project “Early Prevention of Diabetes Complications in people with hyperglycaemia in Europe” (e-PREDICE. FP7-279074) in which we are the responsible for measuring the biomarkers of DR.
• Insulin resistance and obesity: new pathogenic candidates and the study of co-morbidities. The main objective is to investigate the pathogenic mechanisms of obesity and its co-morbidities and to find out new therapeutic targets.
In the setting of the new pathogenic candidates, we are investigating the role of sex hormone binding globulin (SHBG), as well as mitochondrial dysfunction.
Regarding co-morbidities, we are examining the mechanisms by which the lung can be considered a new target of diabetes complications.
• Endothelial dysfunction, dyslipideamia and cardiovascular disease in type 2 diabetes. We are exploring non-classic cardiovascular risk factors. In this setting is worth mentioning our key participation in the project “Preventing cardiovascular ischemic events and arresting their
78
PROgRAMME
P1